Memantina Jaba (Memantine Hydrochloride)

Memantine blocks the phencyclidine site of NMDA receptors in a non‑competitive manner, limiting excessive calcium entry caused by glutamate over‑activation. This reduces excitotoxic injury to neurons while allowing normal synaptic activity, which underlies its benefit in Alzheimer’s disease.

The dosage of Memantina Jaba is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. The prescriber determines the appropriate starting dose and titration schedule according to approved guidelines.

Safety data for memantine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit justifies the potential risk to the fetus or infant, and should be discussed with a healthcare professional.

To request Memantina Jaba, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil, rivastigmine, or galantamine. While cholinesterase inhibitors enhance cholinergic transmission, memantine reduces glutamate‑mediated excitotoxicity; both classes may be used together for complementary effects in moderate to severe disease.

Memantina Jaba should be stored at ambient temperature below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Memantina Jaba is taken orally, usually as a tablet, with or without food. The exact dosing schedule, including the number of tablets per day and any titration steps, is determined by the prescribing physician based on individual patient needs.

Serious adverse reactions, although uncommon, can include hallucinations, severe hypertension, and hypersensitivity reactions such as skin rash or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience these symptoms.

Memantina Jaba is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any excipients in the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists, as these conditions may increase the risk of adverse effects.